A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu), Formulation 2012/2013, when Administered to adult and elderly subjects.

Trial Profile

A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu), Formulation 2012/2013, when Administered to adult and elderly subjects.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Optaflu
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 21 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top